What is CervoMed?
CervoMed is a biotechnology company dedicated to pioneering innovative treatments for age-related neurodegenerative and neurological disorders. The company's core research focuses on addressing the fundamental mechanisms of neuroinflammation and neurodegeneration through the creation of novel small-molecule therapeutics. Its primary therapeutic program is currently under investigation for a range of neurological conditions impacting cognition, language, and motor functions. CervoMed's strategic development efforts are geared towards advancing disease-modifying treatments to meet substantial unmet medical needs and enhance the quality of life for individuals affected by progressive brain disorders.
How much funding has CervoMed raised?
CervoMed has raised a total of $159.9M across 2 funding rounds:
Share Placement
$149.4M
Stock/Share Issuance
$10.5M
Share Placement (2024): $149.4M, investors not publicly disclosed
Stock/Share Issuance (2026): $10.5M, investors not publicly disclosed
What's next for CervoMed?
With the recent infusion of major strategic capital, CervoMed is poised to significantly advance its clinical-stage programs. The enterprise-level funding provides the necessary resources to further its research into novel small-molecule treatments targeting the underlying causes of neurodegenerative diseases. This strategic backing is anticipated to fuel the progression of its lead therapeutic program through critical clinical trials, potentially leading to the development of disease-modifying therapies for conditions with significant unmet medical needs. CervoMed's focus on age-related neurological disorders positions it to address a growing patient population and a substantial market opportunity.
See full CervoMed company page
